Page 70 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

Date Time Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer. “To our knowledge, this is the first study to show how these two major genetic drivers work together to promote tumor growth and metastasis,” Kim said. “We learned that signaling downstream of mutant KRAS directly promotes mutant p53 activity. This discovery provides not only a new therapeutic target but unveils a vast transcriptional network that is activated downstream of these mutant proteins.”

United statesBingbing daiGigi lozanoAmandar wasylishenJithesh augustineJasonb flemingYaan kangTimothyp heffernanFlorencia mcallisterMichael kimChristopher bristowKendra alltonShunbin xiongJenying dengEugene koayYun zhang

Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting

Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting - Data demonstrates activation of STING pathway in patients - - Combination arm of Phase 1 study of SYNB1891 ongoing - News provided by Share this article Share this article CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research (AACR) annual meeting, April 10-15, 2021. SYNB1891 is an investigational drug being evaluated in an ongoing Phase 1 clinical trial for the treatment of solid tumors and lymphoma. SYNB1891 is composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. This mechanism can play a

United kingdomUnited statesFilip jankuDivision of cancer medicineAmerican association for cancer researchUniversity of texas md anderson cancer centerSynlogic incDepartment of investigational cancer therapeuticsAmerican associationCancer researchSynthetic bioticAssociate professorInvestigational cancer therapeuticsCancer medicineSynthetic bioticsPrivate securities litigation reform act

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesMatthew galskyBristol myers squibbIcahn school of medicine at mount sinaiUniversity of texas md anderson cancer centerTisch cancer instituteTranslational researchBladder cancer centerClinical cancer researchMedical oncologyIcahn schoolAssociate directorTisch cancerMount sinai ledNational cancer instituteNational institutes

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

United statesBingbing daiGigi lozanoAmandar wasylishenJithesh augustineJasonb flemingYaan kangTimothyp heffernanFlorencia mcallisterMichael kimChristopher bristowKendra alltonShunbin xiongJenying dengEugene koayYun zhang

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2 Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2 Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1 THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi s Synthorin technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors PARIS - April 9, 2021 - Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April 10 as a late-breaking po

United statesFrance generalEva schaefer jansenArnaud delepineSuzanne grecoFelix lauscherSanofi synthorinJohn reedFilip jankuFara berkowitzSally bainDivision of cancer medicineGlobal head of research developmentAmerican association for cancer researchUniversity of texas md anderson cancer centerMerck co